Impact of Tumor Regional Involvement on Active Surveillance Outcomes: Validation of the Cumulative Cancer Location Metric in a US Population. by Leong, Joon Yau et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Urology Faculty Papers Department of Urology 
5-18-2019 
Impact of Tumor Regional Involvement on Active Surveillance 
Outcomes: Validation of the Cumulative Cancer Location Metric in 
a US Population. 
Joon Yau Leong 
Thomas Jefferson University 
Courtney Capella 
Thomas Jefferson University 
Seth Teplitsky 
Thomas Jefferson University 
Leonard G. Gomella 
Thomas Jefferson University 
Edouard J. Trabulsi 
Thomas Jefferson University 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/urologyfp 
 Part of the Oncology Commons, and the Urology Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Leong, Joon Yau; Capella, Courtney; Teplitsky, Seth; Gomella, Leonard G.; Trabulsi, Edouard J.; 
Lallas, Costas D.; and Chandrasekar, Thenappan, "Impact of Tumor Regional Involvement on 
Active Surveillance Outcomes: Validation of the Cumulative Cancer Location Metric in a US 
Population." (2019). Department of Urology Faculty Papers. Paper 51. 
https://jdc.jefferson.edu/urologyfp/51 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Urology Faculty Papers by an authorized administrator of the Jefferson 
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Joon Yau Leong, Courtney Capella, Seth Teplitsky, Leonard G. Gomella, Edouard J. Trabulsi, Costas D. 
Lallas, and Thenappan Chandrasekar 
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/urologyfp/51 
1 | P a g e  
 
 
Title: Impact of Tumor Regional Involvement on Active Surveillance Outcomes: Validation of the Cumulative 
Cancer Location Metric in a United States Population 
Running Title:  CCLO Validation in a US Active Surveillance Population 
Authors: Joon Yau Leong, BS,1 Courtney Capella, BS,1 Seth Teplitsky, BS,1 Leonard G. Gomella, MD, 1 Edouard 
J. Trabulsi, MD, 1 Costas D. Lallas, MD, 1 Thenappan Chandrasekar, MD 1 
Affiliation: 
1. Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia PA, USA 
Corresponding Author: 
Thenappan Chandrasekar, MD 
Department of Urology 
1025 Walnut Street, Suite 1112 
Philadelphia, PA 19107 





Funding Source: None 
Conflicts of Interest: All authors report no COI. 
Article Type/Category: Original 
Summary 
 Manuscript word count (including abstract): 2736 
 Tables: 3 (+3 supplementary) 









Background: Treatment progression for men on active surveillance (AS) for prostate cancer 
(PCa) is driven primarily by grade and volume progression on isolated prostate biopsies (PBx). 
As PCa is a multifocal disease, regional disease progression over time should be accounted for.  
Objective: To validate the utility of the Cumulative Cancer Location (CCLO) metric, which 
assesses regional core involvement, as described by Erickson et al., in predicting AS outcomes in 
a North American cohort.  
Design, setting, and participants: Single institutional retrospective chart review of all AS 
patients evaluated between 2015-2017.  
Outcome Measurements and Statistical Analysis: CCLO defined as total number of cancer-
positive sextant locations among all PBx to that point in time (range 1-6). Baseline 
demographics and clinical characteristics of the entire cohort were stratified by CCLOΔ, defined 
as the difference between the first and last CCLO. CCLOΔ then correlated to progression to 
treatment and treatment outcomes.  
Results: 261 men met inclusion criteria. Though mean number of biopsies was slightly higher in 
the CCLOΔ 3-5 cohort than the CCLOΔ 0-2 cohort (p=0.006), mean AS follow-up time (3.3 years) 
was not significantly different (p=0.327). As CCLOΔ increased, the proportion of men remaining 
on AS decreased while the proportion of men receiving treatment increased (p<0.001). In men 
undergoing radical prostatectomy, higher CCLOΔ was not associated with higher rates of 
Gleason 7-10 (p=0.38) or pT3 (p=0.52) disease. However, as CCLOΔ increased, upgrading from 
final PBx to RP pathology increased while downgrading decreased (p=0.12). In Kaplan-Meier 
analyses, lower CCLOΔ and lower initial CLO score were associated with the highest 5-year 
treatment-free survival rates (p<0.001). 
Conclusion: Higher regional cancer core involvement is associated with higher rates of 
progression to treatment in AS patients. The CCLO metric is a potentially useful modality in 
stratifying patients for treatment in AS patients among the North American cohort, while not 
compromising disease outcomes. 
Patient Summary: In the North American population, cumulative cancer-positive locations 
among biopsies can be used to predict active surveillance outcomes in men with prostate 
cancer. 
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Since its introduction, widespread screening with serum prostate-specific antigen (PSA) has 2 
facilitated earlier detection of prostate cancer (PCa).1 Although the detection rate of PCa has 3 
increased, a significant proportion of newly diagnosed PCa are found to be clinically localized 4 
low-risk disease.2,3 With improved understanding of the indolent natural history of these low 5 
risk prostate cancers, active surveillance (AS) has emerged as the standard of care for men with 6 
low-risk disease, based on the strength of multiple prospective series that have demonstrated 7 
excellent cancer-specific and overall survival without sacrificing an opportunity for cure in men 8 
who progress to higher risk disease.4-8 9 
 10 
While significant variation exists among AS protocols and international guidelines, eligibility 11 
criteria for AS typically include a combination of PSA level, PSA density, clinical stage, and 12 
prostate biopsy (PBx) data (% positive cores and core volume) on both diagnostic and 13 
confirmatory biopsy.9-12 In men followed on AS, progression to intervention is most commonly 14 
due to pathologic upgrading or increased tumor volume, but clinicians may also consider PSA 15 
kinetics and radiographic upstaging.13,14 Treatment progression due to pathologic upgrading, 16 
increased tumor volume and fast PSA doubling times are reported in 35-50%, 2-63% and 21-17 
44% of AS cohorts, respectively. Progression to definitive treatment due to patient anxiety has 18 
also been reported at rates of 6-9%.4-6 19 
 20 
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Ultimately, the decision to proceed to intervention is driven by the results of the latest PBx, 21 
often considered in isolation from prior PBx results. Given the multifocal nature of PCa and the 22 
sampling error that accompanies freehand transrectal ultrasonography (TRUS) PBx,15-19 Erickson 23 
et al. described a novel method that considers the location of positive cores and regional 24 
involvement over time.20 They first described cumulative cancer locations (CCLO) as a distinct 25 
and powerful predictor of AS outcomes (Supplementary Figure 1). Herein, we validate the utility 26 
of the CCLO metric in predicting AS outcomes in a North American cohort.  27 
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PATIENTS AND METHODS 28 
Following institutional review board approval, retrospective chart review was performed on all 29 
AS patients evaluated in our institution between 2015-2017. At our institution, we utilize the 30 
AUA guidelines for active surveillance in men with very-low risk and low risk patients with 31 
localized PCa, and highly selective low volume localized intermediate risk PCa.12 Men on active 32 
surveillance are followed routinely with PSA testing every 6 months and a PBx every 2 years; 33 
PBx may be completed earlier if there is evidence of a rising PSA or abnormal DRE. Patient 34 
demographics (age, race, clinical stage, preoperative PSA), clinical outcomes (AS progress, 35 
progression to treatment, PCa treatment modality), and radical prostatectomy (RP) pathology 36 
synoptic reports were also recorded. Pathology reports of all PBx for individual patients were 37 
abstracted for date of procedure, number and location of positive cores, and total Gleason 38 
score. Each PBx was reviewed and given a cancer location (CLO) score based on sextant location 39 
containing any positive cancer cores as described by Erickson et al.20 Cumulative CLO (CCLO) 40 
was defined as the sum of all CLOs in all PBx to that point in time, while CCLOΔ was defined as 41 
the difference between the CCLO of the most recent PBx and the CLO of the first PBx 42 
(Supplementary Figure 1). 43 
 44 
All patients were stratified based on CCLOΔ scores (0, 1, 2, 3-5), which was then correlated to 45 
AS clinical outcomes. Descriptive statistics for demographic and outcome comparisons were 46 
performed using analysis of variance (ANOVA) for continuous variables and chi‐square test for 47 
categorical variables. Kaplan‐Meier survival curves were generated to evaluate treatment-free 48 
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progression stratified by CCLOΔ in the entire cohort and sub-stratified by initial CLO; results 49 
were compared with the log-rank test. All statistical tests were two-tailed and a p-value of 50 
<0.05 was considered statistically significant. Analyses were completed using SPSS®, version 51 
23.0.  52 




Patient demographics  54 
Table 1 highlights key demographic data for the entire cohort and stratified by CCLOΔ. Age, 55 
initial PSA, clinical T-stage and risk stratification were not significantly different amongst CCLOΔ 56 
cohorts. Although the mean number of PBx increased with higher CCLOΔ (p=0.006), the time on 57 
active surveillance was not significantly different amongst cohorts (p=0.327).  58 
 59 
Clinical outcomes 60 
Table 2 summarizes clinical outcomes stratified by CCLOΔ. Within the entire cohort, most 61 
patients remained on AS (55.2%), while 42.5% were recommended treatment, with 34.1% 62 
agreeing to undergo treatment.  As CCLOΔ increased, the proportion of men remaining on AS 63 
decreased and the proportion of men receiving treatment increased (p<0.0001). 64 
 65 
Treatment indications and modalities 66 
Table 3 and Supplementary Table 1 summarizes the treatment indications and treatment 67 
modalities utilized within each CCLOΔ cohort, respectively. Across all subsets, the primary 68 
indication for treatment recommendation and receipt was pathologic upgrading on PBx, 69 
ranging between 70-80%, while increased tumor volume was a much less common indication 70 
(20-30%). Radical prostatectomy (RP) was the most common treatment modality, with 54.7% of 71 
men receiving RP and 45.3% receiving radiation therapy with or without hormonal therapy. 72 
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Among the 6 (6.3%) patients who requested treatment due to anxiety, 4 (66.7%) underwent RP 73 
while 2 (33.3%) underwent radiotherapy.   74 
 75 
Analysis of Radical Prostatectomy pathology 76 
Supplementary Table 2 highlights the pathology outcomes in the 52 (19.9%) men who 77 
discontinued AS and underwent RP. Of the 4 patients who voluntarily discontinued AS, 2 had 78 
Gleason 3+3 disease and 2 had Gleason 3+4 disease; all 4 had pT2 disease. A higher CCLOΔ was 79 
not significantly associated with higher rates of intermediate risk (Gleason 7) disease, high risk 80 
(Gleason 8-10) disease or non-localized pT3 disease. 81 
 82 
Progression of disease 83 
Figure 1 depicts treatment-free survival (TFS) based on CCLOΔ for the entire population. Men 84 
with CCLO Δ0 had the best treatment-free survival (5-year TFS 78%), while men with CCLO Δ1-5 85 
had a much higher rate of progression to treatment (5-year TFS 35-58%) (p < 0.001). Further 86 
stratification based on patients initial CLO (Figure 2) demonstrated distinct populations with 87 
superior TFS. Men with the best TFS (5-year TFS 90%) were those with initial CLO 1 and CCLO Δ0 88 
(Figure 2A).  89 
 90 
The swimmer’s plots in Figure 3 depicts the entire patient cohort stratified by treatment 91 
receipt. Figure 3A are patients who remained on AS, including men who were recommended 92 
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treatment but refused. Figure 3B are patients who received treatment, including those who 93 
chose treatment based on personal choice.  94 
  95 




AS has emerged as a standard of care for men with low-risk localized PCa, preserving an 97 
opportunity for curative intervention while minimizing overtreatment and associated adverse 98 
events. AS is characterized by a 30-40% rate of progression to treatment, driven primarily by 99 
grade and volume progression.21 Progression to treatment is typically determined based on a 100 
patient’s most recent PBx, often in isolation from their prior PBx history. Even when considering 101 
volume of disease, clinicians commonly focus on the number and percentage of positive cores 102 
within each PBx rather than the cumulative location of positive cores.22 In 2018, Erickson et al. 103 
found that regional core involvement from the first two PBx (initial and confirmatory) may 104 
represent an additional metric to predicting progression of AS patients to treatment, with 105 
higher CCLO scores predicting poorer AS outcomes.20 Importantly, the CCLO scores account for 106 
regional tumor burden from all prior PBx rather than the most recent PBx alone. As the study 107 
by Erickson et al. was conducted in 3 European centers with relatively homogenous 108 
populations, herein we independently validate the CCLO metric in a North American cohort.23   109 
 110 
While previous studies have established that total number of positive PBx cores is predictive of 111 
AS progression, Erickson et al. showed that CCLOΔ was a powerful predictor for AS outcomes. 112 
Moreover, their study reports that CCLOΔ outperformed number of positive cores in predicting 113 
AS outcomes, with higher CCLOΔ predicting shorter treatment free survival on AS, Gleason 114 
score upgrading and adverse findings on RP.20 In our study, a higher CCLOΔ was also 115 
significantly associated with treatment recommendation and treatment receipt (p<0.0001). 116 
11 | P a g e  
 
 
Kaplan-Meier analyses indicate that patients with higher CCLOΔ have lower 5-year TFS rates. 117 
When stratified by initial volume of disease, it appeared that men with an initial CLO 1 and 118 
CCLOΔ 0 have the greatest benefit from AS, with 5-year TFS rates exceeding 90%. Even men 119 
with initial CLO 1 and CCLOΔ 1-5 had 5-year TFS rates of <65%. These are consistent with 120 
findings by Erickson et al., who demonstrated that higher CCLO at the time of confirmatory 121 
biopsy predicted significantly shorter TFS when stratified by the number of positive cores.20 122 
These results indicate that while initial volume of disease impacts AS outcomes, cumulative 123 
volume progression over time must also be accounted for. 124 
 125 
While Erickson et al. analyzed only the first two PBx (initial and confirmatory), in our study, we 126 
examined all PBx in patients during their entire AS follow-up, enabling better capture of 127 
temporal volume progression.20 The mean number of PBx in the entire cohort was 3.1, with 128 
some patients receiving up to 7 PBx during follow-up. While it would be easy to presume that a 129 
patient’s CCLO would increase proportionately with time on AS, we found that time on AS was 130 
not significantly associated with CCLOΔ. The swimmer’s plot (Figure 3) clearly illustrates the 131 
distinct clinical trajectories of each AS patient over time. Most of the patients who remained on 132 
AS (Figure 3A) had low CCLOΔ scores throughout their surveillance period; many of the men 133 
who remained on AS while having high CCLO scores were recommended treatment but refused. 134 
In contrast, when looking at the course of men ultimately progressing to treatment (Figure 3B), 135 
most of these men had higher CCLOΔ scores. However, the spread of initial CLO scores is 136 
remarkably similar between the groups – indicating that all these men start with low volume 137 
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disease, but a few progresses to higher volume regional disease over time. Yet, as seen by the 138 
side by side comparison of Figures 3A and 3B, there are a subset of patients who progress to 139 
higher volume disease later in their AS follow-up, demonstrating that cumulative volume 140 
progression need not always occur early. This reinforces the need for continued follow-up in all 141 
AS patients. These findings further suggest that CCLOΔ can be a useful surrogate in predicting 142 
outcomes and need for treatment in AS eligible patients in conjunction with other pre-143 
established clinical characteristics.  144 
 145 
Within our cohort, 42% of patients were recommended treatment while 34% eventually 146 
underwent treatment. These rates are consistent with prior literature regarding progression to 147 
treatment in the AS population.21 In contrast to Erickson et al., who found that higher CCLO was 148 
independently associated with adverse RP findings, in our subset of patients who underwent 149 
RP, higher CCLOΔ was not associated with an increased rate of Gleason 7-10 pathology on RP 150 
(p=0.38) or non-localized pT3 upstaging (p=0.52).20 Interestingly, we found that as CCLOΔ 151 
increased, there was a suggestion, although not statistically significant, of increased upgrading 152 
from final PBx to RP pathology (p=0.12). However, in our cohort, 5.8% and 36.5% of patients 153 
had Gleason ≥8 disease and pT3 disease, respectively, on final RP pathology, which was 154 
consistent with previously reported rates in the literature for Gleason 8-10 upgrading (8.7-155 
9.2%) and pT3 upstaging (27.7-43.0%).24,25 Consistent with our data, Dall’Era et al. also found no 156 
association between time on AS and adverse pathological outcomes at the time of RP.26 Overall, 157 
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the literature supports that men on AS undergoing RP have favorable outcomes, which is likely 158 
related to the selective criteria of AS inclusion and the long natural history of low risk PCa. 159 
 160 
As for patients who were recommended or received treatment, we found that Gleason 161 
upgrading was the most common reason for clinicians to discontinue AS and pursue treatment. 162 
In a study of 46 AS patients who subsequently underwent RP, Hong et al. demonstrated that 163 
Gleason upgrading from pattern 3 to 4 or 5 was the most common reason for AS 164 
discontinuation (45.7%) and is also the most prognosticating factor for unfavorable disease on 165 
RP. Increased tumor volume (21.7%) and increased percentage of cancer per biopsy core (8.7%) 166 
were among other common reasons for AS discontinuation.25 These findings suggest the 167 
negative predictive value of a low CCLOΔ. 168 
 169 
Our study is not without its limitations. First, our study design is based on retrospective chart 170 
reviews with its inherent limitations. There was no central pathology review of PBx and final RP 171 
pathology. Our small sample size may also limit the ability to identify important associations 172 
with pathologic outcomes. Having data from a larger number of AS patients would also allow 173 
further analysis of patients with higher initial CLO and higher CCLOΔ and their association with 174 
AS outcomes. Additionally, regional core data depended on accurate labeling of PBx cores at 175 
the time of biopsy. Lastly, as a tertiary care facility, patient selection may be biased towards 176 
higher risk individuals and may not reflect the full spectrum of AS disease pathology. However, 177 
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regardless of these limitations, this cohort still represents a moderate AS cohort with a mean 3-178 
year AS follow-up. 179 
  180 




Our findings suggest that regional core involvement of PCa is associated with progression of 182 
disease in AS patients. The CCLO metric is a potentially useful modality among the North 183 
American cohort for risk stratification in patients managed with AS, without compromising 184 
disease outcomes.  185 
 186 
ACKNOWLEDGEMENTS: None 187 
16 | P a g e  
 
 
REFERENCES / BIBLIOGRAPHY 
1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a 
screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-1161. 
2. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free 
survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 
2001;166(2):416-419. 
3. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613. 
4. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance 
cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272-277. 
5. Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and Longer-Term Outcomes From a 
Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol. 
2015;33(30):3379-3385. 
6. Bokhorst LP, Valdagni R, Rannikko A, et al. A Decade of Active Surveillance in the PRIAS Study: 
An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur 
Urol. 2016;70(6):954-960. 
7. Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for 
localised prostate cancer. Eur Urol. 2013;64(6):981-987. 
8. Welty CJ, Cowan JE, Nguyen H, et al. Extended followup and risk factors for disease 
reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 
2015;193(3):807-811. 
9. Morash C, Tey R, Agbassi C, et al. Active surveillance for the management of localized prostate 
cancer: Guideline recommendations. Can Urol Assoc J. 2015;9(5-6):171-178. 
10. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc 
Netw. 2016;14(1):19-30. 
11. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: 
Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618-629. 
12. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO 
Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 
2018;199(4):990-997. 
13. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a 
reasonable management alternative for patients with prostate cancer: the Miami experience. 
BJU Int. 2008;101(2):165-169. 
14. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the 
PRIAS study. Eur Urol. 2013;63(4):597-603. 
15. Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity 
in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180(3):295-299. 
16. Häggman M, Nordin B, Mattson S, Busch C. Morphometric studies of intra-prostatic volume 
relationships in localized prostatic cancer. Br J Urol. 1997;80(4):612-617. 
17. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation 
prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the 
literature. Eur Urol. 2007;52(5):1309-1322. 
18. Lahdensuo K, Mirtti T, Petas A, Rannikko A. Performance of transrectal prostate biopsies in 
detecting tumours and implications for focal therapy. Scand J Urol. 2015;49(2):90-96. 
19. Han M, Chang D, Kim C, et al. Geometric evaluation of systematic transrectal ultrasound guided 
prostate biopsy. J Urol. 2012;188(6):2404-2409. 
17 | P a g e  
 
 
20. Erickson AM, Luzzago S, Semjonow A, et al. Cumulative Cancer Locations is a Novel Metric for 
Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology. 
2018;1(4):268-275. 
21. Komisarenko M, Martin LJ, Finelli A. Active surveillance review: contemporary selection criteria, 
follow-up, compliance and outcomes. Transl Androl Urol. 2018;7(2):243-255. 
22. Amin MB, Lin DW, Gore JL, et al. The critical role of the pathologist in determining eligibility for 
active surveillance as a management option in patients with prostate cancer: consensus 
statement with recommendations supported by the College of American Pathologists, 
International Society of Urological Pathology, Association of Directors of Anatomic and Surgical 
Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch 
Pathol Lab Med. 2014;138(10):1387-1405. 
23. Montinaro F, Busby GB, Pascali VL, Myers S, Hellenthal G, Capelli C. Unravelling the hidden 
ancestry of American admixed populations. Nat Commun. 2015;6:6596. 
24. Imnadze M, Sjoberg DD, Vickers AJ. Adverse Pathologic Features at Radical Prostatectomy: 
Effect of Preoperative Risk on Oncologic Outcomes. Eur Urol. 2016;69(1):143-148. 
25. Hong SK, Sternberg IA, Keren Paz GE, et al. Definitive pathology at radical prostatectomy is 
commonly favorable in men following initial active surveillance. Eur Urol. 2014;66(2):214-219. 
26. Dall'Era MA, Cowan JE, Simko J, et al. Surgical management after active surveillance  for low-risk 
prostate cancer: pathological  outcomes compared with men undergoing  immediate treatment. 
BJU Int. 2011;107(8):1232-1237. 
 





Table 1: Patient demographics 
 All CCLO Δ0 CCLO Δ1 CCLO Δ2 CCLO Δ3-5 p-value 
Total, N (%) 261 (100.0) 91 (34.9) 80 (30.7) 62 (23.8) 28 (10.7) --- 
Age, years (mean ± SD) 69.5 ± 7.3 68.7 ± 7.4 69.6 ± 8.1 70.5 ± 6.2 69.5 ± 7.3 0.551 
PSA, ng/mL (mean ± SD) 5.3 ± 2.8 5.2 ± 2.8 5.4 ± 2.8 5.5 ± 2.5 5.2 ± 3.2 0.904 
Number of PBx (mean ± SD) 3.1 ± 1.4 2.8 ± 1.2 3.1 ± 1.4 3.2 ± 1.4 3.8 ± 1.5 0.006 
Time on AS, years (mean ± SD) 3.3 ± 2.5 3.1 ± 2.5 3.6 ± 2.6 3.0 ± 2.4 3.7 ± 2.6 0.327 
Initial CLO (median) 1 1 1 1.5 1 --- 
Final CCLO (median) 2 1 2 3.5 4 --- 
Gleason Score at 1st PBx      0.111 
3+3, N (%) 243 (93.1) 85 (93.4) 76 (95.0) 54 (87.1) 28 (100.0)  
3+4, N (%) 18 (6.9) 6 (6.6.) 4 (5.0) 8 (12.9) 0 (0.0)  
Clinical T-stage      0.150 
cT1, N (%) 238 (91.2) 84 (92.3) 69 (86.3) 57 (91.9) 28 (100.0)  
cT2, N (%) 23 (8.8) 7 (7.7) 11 (13.8) 5 (8.1) 0 (0.0)  
Risk Stratification      0.669 
Very low, N (%) 65 (24.9) 22 (24.2) 19 (23.8) 15 (24.2) 9 (32.1)  
Low, N (%) 179 (68.6) 62 (68.1) 57 (71.2) 41 (66.1) 19 (67.9)  
Intermediate, N (%) 17 (6.5) 7 (7.7) 4 (5.0) 6 (9.7) 0 (0.0)  
Abbreviations: PSA – prostate-specific antigen; PBx – prostate biopsy; AS – active surveillance; CLO – cancer location; CCLO – 
cumulative cancer location 
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Table 2: Clinical outcomes for AS 
Clinical Outcomes All CCLO Δ0 CCLO Δ1 CCLO Δ2 CCLO Δ3-5 p-value 
Total, N (%) 261 (100.0) 91 (100.0) 80 (100.0) 62 (100.0) 28 (100.0) --- 
Remained on AS, N (%) 144 (55.2) 71 (78.0) 46 (57.5) 19 (30.6) 8 (28.6) 
<0.0001 
Treatment recommended, N (%) 22 (8.4) 7 (7.7) 4 (5.0) 6 (9.7) 5 (17.9) 
Treatment received, N (%) 89 (34.1) 12 (13.2) 29 (36.3) 33 (53.2) 15 (53.6) 
Treatment requested, N (%) 6 (2.3) 1 (1.1) 1 (1.3) 4 (6.5) 0 (0.0) 
Legend:  
Treatment recommended: patients who were recommended treatment but chose to remain on AS 
Treatment requested: patients who voluntarily opted out of AS to undergo definitive treatment  
Treatment received: patients for whom treatment was recommended and received 
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Table 3: Treatment indications 




Total 22 (100.0) 7 (100.0) 4 (100.0) 6 (100.0) 5 (100.0) 
Gleason upgrading 15 (68.2) 5 (71.4) 3 (75.0) 3 (50.0) 4 (80.0) 
Increased tumor volume 9 (40.9) 2 (28.6) 1 (25.0) 3 (50.0) 3 (60.0) 




Total 89 (100.0) 12 (100.0) 29 (100.0) 33 (100.0) 15 (100.0) 
Gleason upgrading 72 (80.9) 9 (75.0) 26 (89.7) 25 (75.8) 12 (80.0) 
Increased tumor volume 21 (23.6) 2 (16.7) 5 (17.2) 10 (30.3) 4 (26.7) 
Elevated PSA 7 (7.9) 1 (8.3) 3 (10.3) 1 (3.0) 2 (13.3) 








Figure 1: Treatment-free survival for the entire population, stratified by CCLOΔ; Log-rank test: p < 0.001. 
  
Number at	risk
Δ0 90 54 25 12 8 1 0
Δ1 79 53 30 17 6 0 0
Δ2 61 37 15 7 3 1 0
Δ3-5 27 17 11 6 1 0 0
0 2 4 6 8 10 12
Time	on	AS	(years)
Cumulative	number	of	events
Δ0 0 10 13 14 14 14 14
Δ1 0 17 26 29 29 30 30
Δ2 0 17 28 36 37 37 37
Δ3-5 0 7 11 13 15 15 15
0 2 4 6 8 10 12
Time	on	AS	(years)




Figure 2: Treatment-free survival stratified by CCLOΔ; Subset analysis of men with initial CLO 1 (Figure 2A), 




Δ0 65 46 22 11 8 1 0
Δ1 52 35 20 10 3 0 0
Δ2 30 19 9 5 2 1 0
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Figure 3: Swimmer’s Plots of the Entire Cohort, separated in men who stayed on AS (Figure 3A) and men who 
received treatment (Figure 3B). 
Legend:  
Each ● represents a single biopsy. Color coding represents the CCLO at the time based on all prior biopsies. 
In Figure 3A, * represents men recommended for treatment but who refused. 
In Figure 3B, * represents men who chose treatment as a personal choice. 
  




Supplementary Table 1: Treatment modalities 
Types of Treatment All CCLO Δ0 CCLO Δ1 CCLO Δ2 CCLO Δ≥3 
Total, N (%) 95 (100.0) 13 (100.0) 30 (100.0) 37 (100.0) 15 (100.0) 
RP, N (%) 52 (54.7) 10 (76.9) 19 (63.3) 15 (40.5) 8 (53.3) 
XRT +/- ADT, N (%) 43 (45.3) 3 (23.1) 11 (36.7) 22 (59.5) 7 (46.7) 
Abbreviations: RP – radical prostatectomy; XRT – radiation therapy; ADT – hormonal therapy; CCLO – cumulative cancer location. 
*Treatment modalities are not mutually exclusive 
 
Supplementary Table 2: Analysis of RP patients 
RP outcomes All CCLO Δ0 CCLO Δ1 CCLO Δ2 CCLO Δ≥3 p-value 
Total 52 (100.0) 10 (100.0) 18 (100.0) 15 (100.0) 9 (100.0) --- 
Gleason score, 
N (%) 
3+3 9 (17.3) 3 (30.0) 2 (11.1) 2 (13.3) 2 (22.2) 
0.380 
3+4 31 (59.6) 5 (50.0) 9 (50.0) 12 (80.0) 5 (55.5) 
4+3 9 (17.3) 1 (10.0) 6 (33.3) 0 (0.0) 2 (22.2) 
8-10 3 (5.8) 1 (10.0) 1 (5.6) 1 (6.7) 0 (0.0) 
Pathological T-
stage, N (%) 
pT2 33 (63.5) 7 (70.0) 9 (50.0) 11 (73.3) 6 (66.7) 
0.520 
pT3 19 (36.5) 3 (30.0) 9 (50.0) 4 (26.7) 3 (33.3) 
Abbreviations: RP – radical prostatectomy; CCLO – cumulative cancer location 
Supplementary Table 3: Gleason Score comparison of final PBx to RP 
RP outcomes All CCLO Δ0 CCLO Δ1 CCLO Δ2 CCLO Δ≥3 p-value 
Total, N (%) 52 (100.0) 10 (100.0) 18 (100.0) 15 (100.0) 9 (100.0) --- 
Pathology downgrade, N (%) 7 (13.5) 3 (30.0) 4 (22.2) 0 (0.0) 0 (0.0) 
0.119 Pathology consistent, N (%) 35 (67.3) 7 (70.0) 11 (61.1) 10 (66.7) 7 (77.8) 
Pathology upgrade, N (%) 10 (19.2) 0 (0.0) 3 (16.7) 5 (33.3) 2 (22.2) 
Abbreviations: PBx – prostate biopsy; RP – radical prostatectomy; CCLO – cumulative cancer location 





Supplementary Figure 1: A sample patient on active surveillance for prostate cancer with three prior prostate 
biopsies. Based on individual biopsies, the patient only has up to 2 cancer-positive locations (CLO). After 
aggregating CLOs among all prior biopsies, cumulative cancer-positive location (CCLO) is 4. The CCLOΔ in this 
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• CLO	– Cancer	Location
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